Patients with advanced HCC and macroscopic hepatic vascular invasion (n = 97, sorafenib/RT 40/57)

Exclusion (n = 33)
- Child-Pugh class B (n = 27)
- PVTT combined with HVTT (n = 6)

Propensity score analysis (n = 64, sorafenib/RT 36/28)